AZN, Daiichi's Enhertu Gets FDA Nod for Two New Breast Cancer Settings

AstraZeneca’s New FDA Wins Raise Questions On Growth And Valuation

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors

Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

AstraZeneca, Daiichi Sankyo Win US FDA Approval for Datroway to Treat Triple-Negative Breast Cancer

AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast Cancer

AZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid Tumors

Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine

Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026

Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO